Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

Inclusion Criteria:

* Patient has participated in, and completed, a Spectrum-sponsored clinical study with belinostat and did not meet the treatment discontinuation criteria in the study
* Investigator considers this extended belinostat treatment is appropriate for patient, and patient is suitable for the treatment
* Patient agrees to continue belinostat treatment as defined in the original clinical study protocol
* Patient must be willing to give written Informed Consent and must be able to adhere to dosing and visit schedules and meet study requirements
* Patient is willing to practice two forms of contraception, one of which must be a barrier method, from study entry until at least 30 days after the last dose of the study drug

Exclusion Criteria:

* Patient has an active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive belinostat benefit
* Patient is receiving any other treatment modalities including investigational products for their malignancy
* Patient has any medical or non-medical condition that may not be suitable for belinostat treatment, as determined by the investigator and according to the US package insert
* Patient is pregnant or is breastfeeding